Category Archives: Hepatitis C

Hepatitis drug patent application opposed

A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property’s Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India  MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Unavailability of Affordable Hepatitis C Treatments Threatening Malaysian Lives

The World Health Organization (WHO) recently reported that over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.

Posted in Hepatitis C, Sofosbuvir, Uncategorized | 1 Comment

Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition

(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.

Posted in Hepatitis C, Patent Opposition, Patents, TRIPS flexibilities, Uncategorized | Leave a comment

Doctors push Italy to demand generics for pricey hep c drugs

By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS, Uncategorized | Leave a comment